These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 10516002)

  • 21. Coreceptor utilization by human immunodeficiency virus type 1 is not a primary determinant of neutralization sensitivity.
    LaCasse RA; Follis KE; Moudgil T; Trahey M; Binley JM; Planelles V; Zolla-Pazner S; Nunberg JH
    J Virol; 1998 Mar; 72(3):2491-5. PubMed ID: 9499111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies.
    Ly A; Stamatatos L
    J Virol; 2000 Aug; 74(15):6769-76. PubMed ID: 10888615
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Envelope-dependent restriction of human immunodeficiency virus type 1 spreading in CD4(+) T lymphocytes: R5 but not X4 viruses replicate in the absence of T-cell receptor restimulation.
    Vicenzi E; Bordignon PP; Biswas P; Brambilla A; Bovolenta C; Cota M; Sinigaglia F; Poli G
    J Virol; 1999 Sep; 73(9):7515-23. PubMed ID: 10438841
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A preponderance of CCR5(+) CXCR4(+) mononuclear cells enhances gastrointestinal mucosal susceptibility to human immunodeficiency virus type 1 infection.
    Poles MA; Elliott J; Taing P; Anton PA; Chen IS
    J Virol; 2001 Sep; 75(18):8390-9. PubMed ID: 11507184
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Detection of HIV-1 neutralizing antibodies in a human CD4⁺/CXCR4⁺/CCR5⁺ T-lymphoblastoid cell assay system.
    McLinden RJ; Labranche CC; Chenine AL; Polonis VR; Eller MA; Wieczorek L; Ochsenbauer C; Kappes JC; Perfetto S; Montefiori DC; Michael NL; Kim JH
    PLoS One; 2013; 8(11):e77756. PubMed ID: 24312168
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antibody-mediated neutralization of primary isolates of human immunodeficiency virus type 1 in peripheral blood mononuclear cells is not affected by the initial activation state of the cells.
    Zhou JY; Montefiori DC
    J Virol; 1997 Mar; 71(3):2512-7. PubMed ID: 9032392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Differential effects of R5 and X4 human immunodeficiency virus type 1 infection on CD4+ cell proliferation and activation.
    Locher CP; Witt SA; Kassel R; Dowell NL; Fujimura S; Levy JA
    J Gen Virol; 2005 Apr; 86(Pt 4):1171-1179. PubMed ID: 15784911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Mode of coreceptor use by R5 HIV type 1 correlates with disease stage: a study of paired plasma and cerebrospinal fluid isolates.
    Karlsson U; Antonsson L; Repits J; Medstrand P; Owman C; Kidd-Ljunggren K; Hagberg L; Svennerholm B; Jansson M; Gisslén M; Ljungberg B
    AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1297-1305. PubMed ID: 20001314
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Differences in molecular evolution between switch (R5 to R5X4/X4-tropic) and non-switch (R5-tropic only) HIV-1 populations during infection.
    Mild M; Kvist A; Esbjörnsson J; Karlsson I; Fenyö EM; Medstrand P
    Infect Genet Evol; 2010 Apr; 10(3):356-64. PubMed ID: 19446658
    [TBL] [Abstract][Full Text] [Related]  

  • 30. R5 and X4 HIV envelopes induce distinct gene expression profiles in primary peripheral blood mononuclear cells.
    Cicala C; Arthos J; Martinelli E; Censoplano N; Cruz CC; Chung E; Selig SM; Van Ryk D; Yang J; Jagannatha S; Chun TW; Ren P; Lempicki RA; Fauci AS
    Proc Natl Acad Sci U S A; 2006 Mar; 103(10):3746-51. PubMed ID: 16505369
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Identification of determinants on a dualtropic human immunodeficiency virus type 1 envelope glycoprotein that confer usage of CXCR4.
    Cho MW; Lee MK; Carney MC; Berson JF; Doms RW; Martin MA
    J Virol; 1998 Mar; 72(3):2509-15. PubMed ID: 9499115
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple determinants are involved in HIV coreceptor use as demonstrated by CCR4/CCL22 interaction in peripheral blood mononuclear cells (PBMCs).
    Agrawal L; Vanhorn-Ali Z; Alkhatib G
    J Leukoc Biol; 2002 Nov; 72(5):1063-74. PubMed ID: 12429730
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Herpesvirus saimiri-immortalized human lymphocytes: novel hosts for analyzing HIV type 1 in vitro neutralization.
    Vella C; Zheng NN; Easterbrook P; Daniels RS
    AIDS Res Hum Retroviruses; 2002 Sep; 18(13):933-46. PubMed ID: 12230936
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Novel reporter T-cell line highly susceptible to both CCR5- and CXCR4-using human immunodeficiency virus type 1 and its application to drug susceptibility tests.
    Miyake H; Iizawa Y; Baba M
    J Clin Microbiol; 2003 Jun; 41(6):2515-21. PubMed ID: 12791875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemokine receptor-usage of clinical HIV-1 isolates obtained from patients with HIV-1 infection in late clinical stages using PHA-blast.
    Matsuda S; Miyata M
    Microbiol Immunol; 1999; 43(10):967-74. PubMed ID: 10585143
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Development of a cell-based enzyme-linked immunosorbent assay for high-throughput screening of HIV type 1 entry inhibitors targeting the coreceptor CXCR4.
    Zhao Q; Lu H; Schols D; De Clercq E; Jiang S
    AIDS Res Hum Retroviruses; 2003 Nov; 19(11):947-55. PubMed ID: 14678601
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biological characterization and chemokine receptor usage of HIV type 1 isolates prevalent in Brazil.
    Ferraro GA; Mello MA; Sutmöller F; Van Weyenbergh J; Shindo N; Galvão-Castro B; Bou-Habib DC;
    AIDS Res Hum Retroviruses; 2001 Sep; 17(13):1241-7. PubMed ID: 11559423
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two PBMC-based neutralization assays depict low reactivity of both anti-V3 monoclonal antibodies and immune sera against HIV-1 primary isolates.
    Candotti D; Rosenheim M; Huraux JM; Agut H
    J Virol Methods; 1997 Feb; 64(1):81-93. PubMed ID: 9029533
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The N-linked glycan g15 within the V3 loop of the HIV-1 external glycoprotein gp120 affects coreceptor usage, cellular tropism, and neutralization.
    Polzer S; Dittmar MT; Schmitz H; Schreiber M
    Virology; 2002 Dec; 304(1):70-80. PubMed ID: 12490404
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Specific reactions between purified HIV-1 particles and CD4+ cell membrane fragments in a cell-free system of virus fusion or entry.
    Harada T; Tatsumi M; Takahashi H; Sata T; Kurata T; Kojima A
    Microbes Infect; 2004 Apr; 6(5):421-8. PubMed ID: 15109956
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.